ADvantage Therapeutics Inc.
PrivateLast Round
Early Funding
Jul 12, 2023
Total Funding Raised
$10.5M
Momentum Score
50 /100
Company Overview
ADvantage Therapeutics Inc. is a clinical-stage pharmaceutical company founded in 2021 with headquarters in Miami, Florida. The company focuses on developing therapies for neurodegenerative conditions, with a primary emphasis on Alzheimer's Disease (AD). Its lead product candidate, AD04™, is a subcutaneous injectable therapy designed to modulate the immune system to reduce AD pathology. As of late 2023, AD04™ has entered Phase 2b clinical trials in Europe. The company also has a research and development subsidiary, ADvantage Therapeutics GmbH, located at the Vienna BioCenter in Austria. Additionally, the company is exploring other approaches to mitigate neurodegenerative diseases, such as using mRNA technology to increase levels of the Klotho protein, an area of research spun out into a new company, Klothea Bio, in 2024.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2G
Customer Profile
Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ADvantage Therapeutics Inc. Comps
Public and private peers based on sector, stage, and business model.
ADvantage Therapeutics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Jul 12, 2023 | ||||
| Seed | Jun 1, 2022 |
Key People
Founding team and executive leadership
ADvantage Therapeutics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| quadraScope Ventures | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 9, 2025
Preparing for Phase 1B trial of next-generation Klotho therapeutics.
- Sep 26, 2025
AD04 targets mild Alzheimer's for symptomatic relief and disease modification.
ADvantage Therapeutics Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ADvantage Therapeutics Inc.'s valuation, stock price, and market status.
